Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does AVELUMAB Cause Malignant neoplasm progression? 37 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 37 reports of Malignant neoplasm progression have been filed in association with AVELUMAB (BAVENCIO). This represents 1.0% of all adverse event reports for AVELUMAB.

37
Reports of Malignant neoplasm progression with AVELUMAB
1.0%
of all AVELUMAB reports
7
Deaths
9
Hospitalizations

How Dangerous Is Malignant neoplasm progression From AVELUMAB?

Of the 37 reports, 7 (18.9%) resulted in death, 9 (24.3%) required hospitalization.

Is Malignant neoplasm progression Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for AVELUMAB. However, 37 reports have been filed with the FAERS database.

What Other Side Effects Does AVELUMAB Cause?

Death (361) Disease progression (355) Off label use (200) Diarrhoea (153) Infusion related reaction (142) Pyrexia (129) Fatigue (124) Neoplasm progression (119) Dyspnoea (100) Nausea (99)

What Other Drugs Cause Malignant neoplasm progression?

PEMBROLIZUMAB (10,111) NIVOLUMAB (9,363) ENZALUTAMIDE (4,696) CARBOPLATIN (4,177) EVEROLIMUS (3,789) PACLITAXEL (3,484) LETROZOLE (3,445) IPILIMUMAB (3,296) FULVESTRANT (3,221) LENVATINIB (2,929)

Which AVELUMAB Alternatives Have Lower Malignant neoplasm progression Risk?

AVELUMAB vs AVIBACTAM AVELUMAB vs AVIBACTAM\CEFTAZIDIME AVELUMAB vs AVOBENZONE\HOMOSALATE\OCTINOXATE\OCTISALATE\OCTOCRYLENE\OXYBENZONE\TITANIUM DIOXIDE\ZINC AVELUMAB vs AVOBENZONE\HOMOSALATE\OCTINOXATE\OCTISALATE\OXYBENZONE AVELUMAB vs AVOBENZONE\HOMOSALATE\OCTISALATE\OCTOCRYLENE

Related Pages

AVELUMAB Full Profile All Malignant neoplasm progression Reports All Drugs Causing Malignant neoplasm progression AVELUMAB Demographics